Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENERIC DRUG REGULATION

This article was originally published in The Gold Sheet

Executive Summary

...is being closely examined at FDA and the U.S. Pharmacopeia in the search for ways to streamline the approval process and update the standards to match current manufacturing science. FDA’s generics office is implementing a range of strategies aimed at reducing ANDA approval times and addressing workload issues including early review of dissolution testing and eliminating re-reviews of drug master files. Dissolution methods for alternate dosage forms and better coverage of marketed substances and products by USP monographs are other facets of the effort to clarify the regulatory standards for generic products. At a recent USP conference, participants explored the current problems drug product manufacturers face in assuring that excipients will serve the more complex purposes for which they are being used. USP excipient initiatives include updating its guidance on pharmaceutical water.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS000068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel